Research identifies first method for testing, assessing drug treatments for Chagas' disease

Chagas’ disease is a tropical parasitic sickness that currently affects more than 16 million people, with a staggering 100 million at risk, largely in the tropical areas of South and Central America. And yet the main drug used to treat the disease is highly toxic and causes serious side effects.

Now, new research just published by scientists at the University of Georgia has identified for the first time a sensitive method for testing and assessing the efficacy of treatments for Chagas’ disease. The study could lead to new treatments for long-term sufferers of a disease that can be fatal.

“It is the first time we’ve been able to identify a set of measurements to determine whether or not a drug for Chagas actually works,” said Rick Tarleton, distinguished research professor of cellular biology and a faculty member at UGA’s Center for Tropical and Emerging Global Diseases.

The research was published today in the online edition of the journal Nature Medicine. Co-authors, also from the University of Georgia, are postdoctoral associate Juan Bustamante and master’s degree student Lisa Bixby.

The research presents the first and only evidence that the current drug therapies for Chagas’ disease can actually completely cure the infection. Still, current treatments have potentially severe side effects and are thought to be effective in less than 50 percent of those treated. More important, the model the team developed can be used for the development of better drugs against Trypanosoma cruzi, the parasite that causes the disease.

“We also found that the immunological markers of cure in this system, which we developed in mice, provide a means to monitor drug treatment efficacy in humans, something that has been the biggest impediment to developing new drugs,” said Tarleton.

There’s a fourth finding more important to the big picture of immunology, however. This study shows that chronic infections do not by default exhaust the immune system.

“Current dogma on chronic infections is that constant stimulation of the immune system eventually wears it out, which is one of the problems in treating such disorders as HIV/AIDS,” said Tarleton. “This study shows that one can have an infection for more than a year, but, when cured, the immune system develops a stable, protective memory.”

This idea of “memory” is at the heart of the study, and it involves T-cells, specifically one kind called cytotoxic or “killer” T-cells, which are blood-borne white blood cells that destroy T. cruzi-infected cells in the case of Chagas’ disease and virally infected and tumor cells in other cases. Tarleton and his colleagues documented the development of stable killer T-cell “memory” following drug-induced cure of a chronic infection. In other words, when the body is cleared of parasites, the killer T-cells, which may have been “exhausted” by battling the persistent infection, bounce back and recall how to do their job.

The implications of the study could be considerable, Tarleton said. The T. cruzi parasite is passed to humans from the bite of blood-sucking assassin bugs, which go by many names, including “kissing bugs.” The infection can also be acquired through contaminated blood transfusions and by eating food contaminated with parasites.

In its first stages, the disease often causes no more than a local swelling at the point of the bite. This acute phase often passes, but the malady, if untreated, can then enter a chronic phase that can last for decades and cause heart disease and intestinal disorders. In many cases, Chagas’, named for the Brazilian scientist who first described it nearly a century ago, is fatal.

While several hundred thousand people in the United States may have the disease, these are largely immigrants from Latin American countries. The disease, however, is a major public health issue in all of South America and kills as many as 50,000 people each year, according to some estimates, making it the most significant parasitic disease of the Americas, Tarleton said.

Source: University of Georgia

Related stories:

Researchers add crucial information on how the body's T cells react to parasitic diseases
In the 1980s, the phrase "T cell count" burst into the world's medical vocabulary as thousands and then millions of patients died of AIDS. The public began to understand the crucial importance of T cells--cellular Pac-Men that roam the bloodstream gobbling up infection and guarding against future attacks.
Study finds multiple neglected tropical diseases effectively treated with drugs
The neglected tropical diseases are a group of 13 infectious diseases, including elephantiasis, hookworm, African sleeping sickness and trachoma, which affect more than 1 billion people worldwide, most of whom live in extreme poverty. In a study published in the most recent Journal of the American Medical Association, Madhuri Reddy, M.D., M.Sc., a geriatrician at Hebrew SeniorLife in Boston, says that treating two or more of them simultaneously for only pennies per dose can facilitate treatment of these diseases.
Data on life expectancy show many countries clustered in high mortality traps
Growing recognition of the importance of health as a contributing factor to economic development and societal change has prompted the Proceedings of the National Academy of Sciences (PNAS) to add a new subsection in Sustainable Health to its existing section on Sustainable Development.
Researchers Endorse Global Early Warning System to Prevent Pandemics
Could the HIV pandemic have been prevented? Nathan Wolfe, professor of epidemiology at the UCLA School of Public Health, says yes, and he's working to prevent the next one.
Put sleeping sickness bug to sleep
An Israeli researcher has found a way to kill the parasite that causes sleeping sickness.
Leeches ferry infection among newts
Parasite-carrying bloodsucking leeches may be delivering a one-two punch to newts, according to biologists, who say the discovery may provide clues to disease outbreaks in amphibians.
Fundamental Discovery About the Fracture of Human Bone: It's All in the 'Glue'
A startling discovery about the properties of human bone has been made by scientists at the University of California, Santa Barbara.
The scientists describe their results –– finding a sort of "glue" in human bone –– in the cover story of the August issue of the international scientific journal, Nature Materials. The article was published on-line on July 17. It describes how healthy bone resists fracture and how unhealthy bone fractures at the molecular level. Included with the article are the highest resolution images of bone ever published, which reveal the location of the adhesive or "glue" that holds together mineralized collagen fibrils (protein fibers) of bone.
Parsing the genome of a deadly brain tumor
The most comprehensive to-date genomic analysis of a cancer – the deadly brain tumor glioblastoma multiforme – shows previously unrecognized changes in genes and provides an overall view of the missteps in the pathways that govern the growth and behavior of cells, said members of The Cancer Genome Atlas Research Network in a report that appears online today in the journal Nature.

News discussion:

Medicine & Health news